{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 9/80', 'Amendment 2 (31-July-2019)', 'The overall reason for this amendment:', 'Update of information based on Investigator Brochure Edition 6 (28-Jun-2019), incorporation of', 'changes to address changes in CSP Version 1.00 for', 'corrections of errors and', '.', 'clarifications.', 'The changes made to the CSP GLPG1690-CL-204 Version 3.00 (13 Nov 2018), are listed below,', 'with a brief rationale of each change and the applicable sections.', 'The changes made in CSP', 'Version 1.00 (12-Mar-2019) have been implemented, with the', 'exception of the change to Inclusion Criterion 8 regarding body mass index (BMI), which was', 'modified in the CSP for', 'In this General CSP Version 4.00, Inclusion Criterion 8 remains', 'unchanged (BMI 18-35 kg/m\u00b2) except in', 'where a BMI of 18-30 kg/m\u00b2 applies.', 'Applicable Sections:', 'Section 4.5.1 Inclusion Criteria', 'All other changes as detailed in the separate table below for CSP', 'Version 1.00 (12-Mar-', '2019)', \"The current Investigator's Brochure is now Edition 6.00 (28-Jun-2019). The information on\", 'GLPG1690 has been updated.', 'Applicable Sections:', 'Section 2 Introduction', 'Section 4.4 Potential risks and Benefits', 'Section 5.1 Identity of the Investigational Medicinal Product', 'Section 4.5.3.2 Prior and Concomitant Medications', 'In addition, the objective and endpoint definitions were aligned.', 'Applicable Sections:', 'Summary', 'Section 3.3 Other Objectives', 'Section 4.3.3. Other Endpoints', 'The period of time prior to the treatment period during which subjects may not take excluded', 'medications has been clarified.', 'Applicable Sections: Section 4.5.2 Exclusion Criteria', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 10/80', \"The period of time prior to screening during which subjects' medications should be stable has been\", 'clarified.', 'Bosentan has been added to the list of excluded medications, and hydroxychloroquine to the list of', 'medication known to prolong QT interval (to be used with caution).', 'The prohibition of B-cell depleting agents has been broadened to \"other monoclonal', 'antibodies\".', 'Applicable Sections:', 'Section 4.5.3.2 Prior and Concomitant Medications', 'Appendix 2 Known Strong CYP3A4 Inducers and Potent P-gp Inducers', 'Appendix 5 Medication Known to Prolong QT interval', 'The list of clinical laboratory tests has been revised', '-', 'Mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin', 'concentration have been added to the hematology parameters.', '-', 'Creatine kinase has been added to the serum chemistry parameters.', '-', 'Ketone have been added to the urinalysis parameters', 'Applicable Section: Section 6.6.2 Clinical laboratory evaluations', 'The ECG parameter QTcB will not be derived.', 'Applicable Section: Section 6.6.5 12-lead Electrocardiogram', 'An interim analysis at Week 16 is no longer planned. The sponsor decided that an interim analysis', 'is no longer required.', 'A clarification has been added that the primary analysis of efficacy will be performed at Week 24,', 'at the end of the double-blind treatment period.', 'Applicable Sections:', 'Section 4.6.2 Blinding and Unblinding', 'Section 7 Statistical Methods', 'New section - Section 7.3.2. Primary Analysis', 'Renumbered section - Section 7.3.27.3.3 Interim Analysis', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 11/80', 'CSP', 'Version 1.00 (12-Mar-2019)', 'The overall reason for this amendment:', 'The changes made to the CSP GLPG1690-CL-204 Version 3.00, (13-Nov-2018), are listed below,', 'reflecting a brief rationale of each change and the applicable sections.', 'The information on fertility has been updated with the results of nonclinical male and female', 'fertility studies in rats. The recommendation for males to store sperm before taking part in the study', 'has been removed, and replaced with guidance for male subjects to withdraw if they intend to father', 'a child.', 'Applicable Sections:', 'Section 4.4 Potential Risks and Benefits', 'Section 4.5.3.1.2 Precautions for Sexual Intercourse: Male subjects', \"It is clarified that all adverse events (AEs) will be collected until the subject's last follow-up Visit.\", 'Applicable Sections:', 'Section 4.1 Overall Clinical Study Design', 'Section 6.6.1 Adverse Events', 'Section 6.11 Schedule of Activities', 'Section 7.3.5 Analysis of Safety Data', 'The specific liver function test (LFT) threshold at Visit 2 was removed; the LFT criteria for', 'treatment discontinuation apply to all study visits.', 'Applicable Sections:', 'Section 4.5.4. Treatment Discontinuation (Temporarily and Permanently), Subject Withdrawal, and', 'Study Termination', 'A urine pregnancy test was added at Visit 2 (Day 1) and Follow-up Visit 1.', 'Applicable Sections:', 'Section 4.5.1 Inclusion Criteria', 'Section 4.5.3.1.1 Precautions for Sexual Intercourse: Female subjects', 'Section 6.11 Schedule of Activities', 'Inclusion criterion 8 regarding body mass index (BMI) was modified to include subjects with BMI', '18-30 kg/m\u00b2 in the study.', 'Applicable Sections:', 'Section 4.5.1 Inclusion Criteria', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}